Method for producing optically active 1,4-benzothiazepine-1-oxide derivatives

A method using a titanium compound and chiral diol in a solvent achieves efficient asymmetric oxidation of 1,4-benzothiazepine-1-oxide derivatives, addressing inefficiencies in existing methods and enabling high-purity, low-hygroscopicity salts for industrial production.

JP7595011B2Active Publication Date: 2024-12-05AETAS PHARMA
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2021534059
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-22
Filing Date
2020-07-22
Publication Date
2024-12-05
Estimated Expiration
2040-07-22

AI Technical Summary

Technical Problem

Existing methods for producing optically active 1,4-benzothiazepine-1-oxide derivatives are inefficient, require discarding unneeded enantiomers, and are not suitable for industrial scale-up due to equipment limitations, and there is a lack of effective methods for asymmetric oxidation of the sulfur atom in the heterocycle.

Method used

A method involving a titanium compound, a chiral diol compound, and an oxidizing agent in a solvent is used to asymmetrically oxidize 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine, producing optically active 1,4-benzothiazepine-1-oxide derivatives without the need for bases like diisopropylethylamine, allowing for high purity and yield.

Benefits of technology

The method achieves high enantiomeric excess and high yield of optically active 1,4-benzothiazepine-1-oxide derivatives with improved optical purity and safety, and produces salts with low hygroscopicity, suitable for industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595011000064
    Figure 0007595011000064
  • Figure 0007595011000065
    Figure 0007595011000065
  • Figure 0007595011000066
    Figure 0007595011000066
Patent Text Reader

Abstract

The present invention addresses the problem of providing an efficient asymmetric synthesis method for an optically active 1, 4-benzothiazepine-1-oxide derivative. [Solution] According to the present invention, an optically active 1, 4-benzothiazepine-1-oxide derivative is efficiently produced by reacting a 1, 4-benzothiazepine derivative or a salt thereof with a reagent containing a titanium compound, a chiral diol compound and water, and an oxidant in a solvent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing an optically active 1,4-benzothiazepine-1-oxide derivative, and a salt thereof. [Background technology]

[0002] Patent Document 1 discloses that one of the optical isomers of a 1,4-benzothiazepine-1-oxide derivative (first optical isomer component) gently increases heart rate and blood pressure and is useful as a therapeutic or preventive drug for atrial fibrillation and heart failure. It also discloses that its enantiomer (second optical isomer component) has an opposing pharmacological action and decreases heart rate and blood pressure.

[0003] Patent Documents 1 and 2 disclose a method for producing a sulfoxide-form 1,4-benzothiazepine-1-oxide derivative by reacting a sulfur atom in a heterocycle of a 1,4-benzothiazepine derivative with metachloroperbenzoic acid (mCPBA) as an oxidizing agent.

[0004] Patent Document 1 also discloses a method for optically resolving a racemic mixture of a 1,4-benzothiazepine-1-oxide derivative using a chiral column to separate the first and second components of the optical isomers. However, in optical resolution using a chiral column, it is necessary to discard the unnecessary enantiomers, making it difficult to improve the total yield of the entire process. In addition, for the purpose of scaling up the production of a specific optical isomer, the method using a chiral column is not an industrially satisfactory method in terms of equipment.

[0005] Furthermore, Patent Document 1 discloses a hydrochloride salt as a salt of 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide. It is generally known that compounds in the form of hydrochloride tend to be highly hygroscopic, but Patent Document 1 does not disclose anything about the crystals or hygroscopicity of the hydrochloride salt of 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide.

[0006] Patent Document 3 describes JTV-519, a 1,4-benzothiazepine derivative, and its dioxide (SO2) derivative S23. It also describes that S23 can be obtained by oxidizing JTV-519 with hydrogen peroxide. However, Patent Document 3 does not provide any specific disclosure regarding the oxidation reaction. Furthermore, there is no specific disclosure regarding the production of an oxide of a sulfoxide rather than a dioxide, and naturally there is no description regarding an asymmetric synthesis reaction of an optically active sulfoxide.

[0007] Several methods are known for the asymmetric oxidation of sulfides. One of them is a method of producing an optically active sulfoxide from a sulfide using a complex containing a transition metal-containing compound and an optically active ligand as a catalyst. However, there has been no example of oxidizing the sulfur atom of benzothiazepine, and the present inventors have not been able to find any example of oxidizing a sulfur atom present in a heterocycle. There is no reference example for the asymmetric oxidation of 1,4-benzothiazepine derivatives, and chiral complexes containing transition metals as catalysts are relatively expensive, so it was thought that it would be difficult to establish an industrial method for producing 1,4-benzothiazepine-1-oxide derivatives using the catalyst.

[0008] As a different method, an asymmetric oxidation method using a reactant containing a titanium compound and a diol ligand (Kagan's Reagent) is known, but even with this method, there are very few cases in which a sulfur atom present in a heterocycle is oxidized. The present inventors referred to a report (Non-Patent Document 1) in which an asymmetric oxidation of a 1,5-benzothiazepine derivative was attempted. However, this document does not disclose the substituent R 1 It was reported that contributes to the enantioselective oxidation reaction of sulfides. However, since the 1,4-benzothiazepine derivatives handled by the present inventors do not have a substituent at the 9-position of the benzothiazepine ring, it was understood that the method described in the document is not appropriate to apply as it is. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] International Publication No. 2016 / 017448 [Patent Document 2] International Publication No. 2010 / 098080 [Patent Document 3] International Publication No. 2007 / 024717 [Non-patent literature]

[0010] [Non-Patent Document 1] Makino K et al., Tetrahedron Lett., 2017, Vol.58, pp.2885-88 [Non-Patent Document 2] Song ZJ et al., PNAS, 2004, Vol.101, pp.5776-81 Summary of the Invention [Problem to be solved by the invention]

[0011] An object of the present invention is to provide an efficient method for asymmetric synthesis of optically active 1,4-benzothiazepine-1-oxide derivatives. Another object of the present invention is to provide a salt of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide having excellent physical properties (a salt with low hygroscopicity). [Means for solving the problem]

[0012] The present inventors referred to a literature (Non-Patent Document 2) in which the sulfur atom of a heterocyclic compound, a 1,4-benzoxathiin derivative, was asymmetrically oxidized, and attempted to apply the Kagan reaction system described in the literature. However, when 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine was used as a substrate, the desired enantioselective oxidation reaction could not be achieved. Therefore, the present inventors further conducted intensive studies to solve the above problem, and found that an optically active 1,4-benzothiazepine-1-oxide derivative can be efficiently produced by reacting a 1,4-benzothiazepine derivative in the presence of a reactant containing a titanium compound, a chiral diol compound, and water, and an oxidizing agent in a solvent under appropriate operations. The present inventors also discovered a salt of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide that has low hygroscopicity, and thus completed the present invention.

[0013] That is, specific embodiments of the present invention include the following [1] to

[37] . [1] Formula (I)

[0014] [ka]

[0015] [In the formula, X represents a hydrogen atom or a substituent.] or a salt thereof with a titanium compound, a chiral diol compound, and a reactant containing water, and an oxidizing agent in a solvent,

[0016] [ka]

[0017] [In the formula, * represents an optically active substance, and X represents a hydrogen atom or a substituent.] A method for producing an optically active compound represented by the formula:

[0018] [2] The method for producing the compound represented by formula (I) or a salt thereof according to the above [1]. [3] The method for producing the compound represented by formula (I) or a salt thereof according to the above [1], wherein the compound represented by formula (I) or a salt thereof is a hydrochloride, a fumarate, a mandelate or a sulfonate of the compound represented by formula (I). [4] The compound represented by formula (I) or a salt thereof is represented by the following formula (III):

[0019] [ka]

[0020] [In the formula, R represents a hydrogen atom or a hydroxyl group.] or a salt thereof, and the compound represented by formula (II) or a salt thereof is represented by the following formula (IV):

[0021] [ka]

[0022] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.] or a salt thereof. [5] The production method according to the above [4], wherein in the formula (III) and the formula (IV), R is a hydrogen atom. [6] The method for producing the compound represented by formula (III) or a salt thereof according to the above [4] or [5]. [7] The method according to the above [4] or [5], wherein the compound represented by formula (III) or a salt thereof is a hydrochloride, a fumarate, a mandelate or a sulfonate of the compound represented by formula (III). [8] The method for producing any one of [1] to [7] above, wherein the titanium compound is titanium tetraisopropoxide. [9] The diol compound is represented by the following formula (Va):

[0023] [ka]

[0024] [In the formula, R 1 is optionally substituted C 2-6 It represents an alkyl group or benzyl. or a tartaric acid diester represented by the following formula (Vb):

[0025] [ka]

[0026] [The symbols in the formula are as defined above.] The method for producing any one of the above [1] to [8], wherein the tartaric acid diester is represented by the formula:

[10] The method according to [9] above, wherein the tartrate diester represented by formula (Va) or formula (Vb) is a tartrate diester selected from the group consisting of diethyl tartrate, diisopropyl tartrate, and dibenzyl tartrate.

[11] The method according to any one of [1] to

[10] above, wherein the oxidizing agent is an aqueous t-butyl hydroperoxide solution or cumene hydroperoxide.

[12] The method according to

[11] above, wherein the oxidizing agent is cumene hydroperoxide.

[13] The method for producing any one of the above [1] to

[12] , wherein the solvent is selected from the group consisting of toluene, trichloromethane, and ethyl acetate.

[14] The method according to

[13] above, wherein the solvent is toluene.

[0027]

[15] Formula (VI)

[0028] [ka]

[0029] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.] The mandelic acid salt of the optically active compound represented by formula (IV) is represented by:

[16] A mandelate salt of the optically active compound according to the above

[15] , wherein in formula (VI), R is a hydrogen atom.

[0030]

[17] Formula (VII)

[0031] [ka]

[0032] [In the formula, R 2 represents an optionally substituted hydrocarbon group, * represents an optically active substance, and R represents a hydrogen atom or a hydroxyl group. A sulfonate salt of an optically active compound represented by formula (IV):

[18] A sulfonate of the optically active compound according to

[17] above, wherein the sulfonate is a p-toluenesulfonate or a methanesulfonate.

[19] A sulfonate salt of the optically active compound according to

[17] or

[18] above, wherein R is a hydrogen atom.

[0033]

[20] Formula (IV)

[0034] [ka]

[0035] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.] The method includes a step of mixing a salt of an optically active compound represented by the formula (I) selected from the group consisting of a fumarate, a mandelate, a p-toluenesulfonate, and a methanesulfonate with a solution containing hydrogen chloride in a solvent, The following formula (VIII)

[0036] [ka]

[0037] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.] A method for producing the hydrochloride of an optically active compound represented by the formula:

[21] The method for producing the above

[20] , wherein R is a hydrogen atom.

[22] The method according to

[20] or

[21] above, wherein the solvent is tetrahydrofuran, acetonitrile, ethyl acetate, or a mixture of two or more of the above three.

[23] The method according to

[22] above, wherein the solvent is ethyl acetate, a mixture of ethyl acetate and acetonitrile, or a mixture of tetrahydrofuran and acetonitrile.

[24] The method for producing the above

[23] , wherein the solvent is a mixture of tetrahydrofuran and acetonitrile.

[25] The method for producing any one of the above

[20] to

[24] , wherein the solution containing hydrogen chloride is methanol, ethanol, or ethyl acetate.

[26] The method according to

[25] above, wherein the solution containing hydrogen chloride is ethyl acetate.

[27] The method for producing any one of the above

[20] to

[26] , wherein the optically active compound represented by formula (IV) and hydrogen chloride contained in the solution containing hydrochloric acid are used in an equivalent ratio of 1:1.1 to 1:1.5.

[28] The method for producing any one of the above

[20] to

[27] , wherein the salt selected from the group consisting of fumarate, mandelate, p-toluenesulfonate, and methanesulfonate is a mandelate.

[29] The method for producing the mandelate according to

[28] above, wherein the mandelate is an (R)-mandelate.

[0038]

[30] The method for producing any one of the above [1] to

[14] , wherein the optically active compound is an optically active compound of the (R) form.

[31] The method according to any one of [1] to

[14] above, wherein the optically active compound is an (S)-form optically active compound.

[0039]

[32] A mandelate salt of the optically active compound according to

[15] or

[16] above, wherein the optically active compound is an optically active compound of the (R) form.

[33] A mandelate salt of the optically active compound according to

[15] or

[16] above, wherein the optically active compound is an (S)-form optically active compound.

[0040]

[34] A sulfonate salt of the optically active compound according to any one of

[17] to

[19] above, wherein the optically active compound is an optically active compound of the (R) form.

[35] A sulfonate salt of the optically active compound according to any one of

[17] to

[19] above, wherein the optically active compound is an optically active compound of the (S) form.

[0041]

[36] The method for producing any one of the above

[20] to

[29] , wherein the optically active compound is an optically active compound of the (R) form.

[37] The method for producing any one of the above

[20] to

[28] , wherein the optically active compound is an (S)-form optically active compound. Effect of the Invention

[0042] According to the present invention, optically active 1,4-benzothiazepine-1-oxide derivatives can be produced efficiently with high purity and in high yield. In the asymmetric oxidation method of sulfur atoms, it has been reported that the enantiomeric excess is significantly improved by adding diisopropylethylamine to the reaction system (for example, Non-Patent Document 2), but the method of the present invention can achieve an asymmetric oxidation reaction showing a high enantiomeric excess (high optical purity) without adding a base such as diisopropylethylamine. The method of the present invention is advantageous in that it does not require diisopropylethylamine, which is skin irritant and flammable and requires careful handling. In addition, when comparing the presence and absence of diisopropylethylamine in the reaction system, the post-step of separating and purifying the desired product (for example, the compound represented by formula (IV'-a) or a salt thereof) from the reaction solution after the completion of the oxidation reaction can be carried out more quickly and simply in the latter case. In other words, the method of the present invention, which does not use diisopropylethylamine, realizes a reaction that is quick, simple, and safe, and is low-cost. Furthermore, according to the present invention, it is possible to provide a salt of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine having excellent physical properties (a salt with low hygroscopicity). [Brief description of the drawings]

[0043] [Figure 1] FIG. 1 shows the dynamic vapor sorption curve (DVS) of the hydrochloride salt of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide. [Diagram 2] FIG. 2 shows the dynamic vapor sorption curve (DVS) of the p-toluenesulfonate salt of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide. [Diagram 3]FIG. 3 shows the dynamic vapor sorption curve (DVS) of the (R)-mandelate salt of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0044] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail with reference to the accompanying drawings.

[0045] The compounds represented by formulas (I), (II), (III), (III'), (IV), (IV'), (IV'-a), and (IV'-b), etc., and the definitions of each symbol in the formulas are described in detail below. The compound represented by the formula (I) shown below is a 1,4-benzothiazepine derivative used as a substrate in the method for producing an optically active 1,4-benzothiazepine-1-oxide derivative (compound represented by the formula (II) below) of the present invention.

[0046] [ka]

[0047] [ka]

[0048] In formula (I) and formula (II), X represents a hydrogen atom or a substituent. The "substituent" represented by X is a formyl group, a carboxy group, C 1-6 Alkyl-carbonyl group, C 2-6 Alkenyl-carbonyl group (e.g., acryloyl, crotonoyl), C 3-10 Cycloalkyl-carbonyl group (e.g., cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl), C 3-10 Cycloalkenyl-carbonyl group (e.g., 2-cyclohexenecarbonyl), C 6-14 Aryl-carbonyl group, C7-16 Aralkyl-carbonyl group;

[0049] [ka]

[0050] [wherein R represents a hydrogen atom or a hydroxyl group]; and the following formula (X):

[0051] [ka]

[0052] [In the formula, Y represents a leaving group.] Examples of the above-mentioned are represented by the following formula: Examples of the leaving group represented by Y include a halogen atom; an optionally halogenated C such as methanesulfonyloxy, ethanesulfonyloxy, trichloromethanesulfonyloxy, and trifluoromethanesulfonyloxy. 1-6 Alkylsulfonyloxy groups; C which may have a substituent such as phenylsulfonyloxy, m-nitrophenylsulfonyloxy, p-toluenesulfonyloxy, naphthylsulfonyloxy, etc. 6-10 Arylsulfonyloxy groups (e.g., C 1-6 Alkyl group, C 1-6 C optionally having 1 to 3 substituents selected from an alkoxy group and a nitro group 6-10 arylsulfonyloxy groups; and optionally halogenated acyloxy groups such as trichloroacetoxy and trifluoroacetoxy. Y is particularly preferably a halogen atom. X is particularly preferably a substituent represented by formula (IX). R is preferably a hydrogen atom.

[0053] A preferred example of formula (I) is a compound represented by the following formula (III):

[0054] [ka]

[0055] [In the formula, R represents a hydrogen atom or a hydroxyl group.] More preferred among the compounds represented by formula (III) is a compound represented by the following formula (III'), that is, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine.

[0056] [ka]

[0057] A preferred example of the compound represented by formula (II) which is the product of the process of the present invention is the compound represented by the following formula (IV).

[0058] [ka]

[0059] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.] A more preferred example of the compound represented by formula (II) is the compound represented by the following formula (IV'), i.e., 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide.

[0060] [ka]

[0061] [In the formula, * indicates an optically active substance.] An example of the compound represented by formula (IV') is the compound represented by the following formula (IV'-a), that is, (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide.

[0062] [ka]

[0063] Analysis by the present inventors has revealed that (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide is the same compound as the "first optical isomer of the compound represented by formula [IV]" in Patent Document 1. This compound has the property of gently increasing heart rate and blood pressure and improving hemodynamics, and is useful as a medicine for improving heart failure, etc.

[0064] Another example of the compound represented by formula (IV') is the compound represented by the following formula (IV'-b), i.e., (S)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide.

[0065] [ka]

[0066] Analysis by the present inventors has revealed that (S)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide is the same compound as the "second optical isomer component of the compound represented by formula [IV]" in Patent Document 1. The compound represented by formula (IV'-a) and the compound represented by formula (IV'-b) can be separated and identified, for example, by the method described in Patent Document 1.

[0067] A particularly preferred example of the compound represented by formula (IV') is (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide represented by formula (IV'-a).

[0068] The compounds represented by formula (I), formula (II), formula (III), formula (III'), formula (IV), formula (IV'), formula (IV'-a), and formula (IV'-b) may be in the form of a salt. Examples of the salt of the compound include salts with inorganic acids, salts with organic acids, and salts with acidic amino acids. Suitable examples of salts with inorganic acids include salts with hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, sulfurous acid, phosphoric acid, phosphorous acid, carbonic acid, bicarbonate, and the like. Suitable examples of salts with organic acids include salts with carboxylic acids (i.e., organic compounds having one or more carboxy groups; specific examples include formic acid, acetic acid, benzoic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, mandelic acid, citric acid, succinic acid, malic acid, etc.); and salts with sulfonic acids (i.e., organic compounds having one or more sulfo groups; specific examples include methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, etc.). Suitable examples of salts with acidic amino acids include salts with aspartic acid, glutamic acid, and the like. Of the above salts, pharma- ceutically acceptable salts are preferred, and among these, salts of hydrochloric acid, fumaric acid, oxalic acid, citric acid, tartaric acid, mandelic acid, and sulfonic acid are preferred. More preferred are mandelic acid and sulfonic acid salts. Among the "sulfonic acids", those represented by the following formula (XI):

[0069] [ka]

[0070] [In the formula, R 2 represents an optionally substituted hydrocarbon group. Preferred is a salt with a sulfonic acid represented by the following formula: In the above formula (XI), R 2 Preferred examples of the "hydrocarbon group" in the "optionally substituted hydrocarbon group" represented by the formula: 1-6 Alkyl group, C 3-10 Cycloalkyl groups, C 6-14 Aryl group, C 7-16 Aralkyl groups, among which C 1-6 Alkyl group and C 6-14 Aryl groups are preferred, C 6-14 Aryl groups are more preferred. In the above formula (XI), R 2 is preferably optionally substituted C 6-14 is an aryl group; more preferably an optionally substituted phenyl group; and even more preferably C 1-6 It is a phenyl group which may be substituted with an alkyl group; particularly preferred is a phenyl group which may be substituted with methyl. Specifically, the sulfonic acid represented by the above formula (XI) is preferably methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, or p-toluenesulfonic acid, and more preferably p-toluenesulfonic acid. The compounds represented by formula (III) and formula (III') may be in the free form or in the form of a salt, but are preferably in the free form. The compounds represented by formula (IV), formula (IV'), formula (IV'-a) and formula (IV'-b) may be in the free form or in the form of a salt, but the salt form is preferred. As the salt of the compound, salts with hydrochloric acid, oxalic acid, fumaric acid, mandelic acid and sulfonic acid are preferred, salts with hydrochloric acid, mandelic acid and p-toluenesulfonic acid are more preferred, and salts with mandelic acid are most preferred. Preferred examples of the salt with mandelic acid include the compounds of the following formula (VI) and formula (VI').

[0071] [ka]

[0072] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.]

[0073] [ka]

[0074] [In the formula, * indicates an optically active substance.] The mandelic acid to be the salt is preferably an optically active substance. When the compounds represented by formulas (IV) and (IV') are in the (R) form, (R)-mandelic acid is preferred, and when the compounds represented by formulas (VII) and (VII') are in the (S) form, (S)-mandelic acid is preferred.

[0075] Preferred examples of the salt with sulfonic acid include the compounds of the following formula (VII) and formula (VII').

[0076] [ka]

[0077] [In the formula, R 2 represents an optionally substituted hydrocarbon group, * represents an optically active substance, and R represents a hydrogen atom or a hydroxyl group.

[0078] [ka]

[0079] [In the formula, * indicates that the compound is optically active, R indicates a hydrogen atom or a hydroxyl group, and R 2 represents an optionally substituted hydrocarbon.

[0080] Preferred examples of the salt with hydrochloric acid include the compounds of the following formulae (VIII) and (VIII').

[0081] [ka]

[0082] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.]

[0083] [ka]

[0084] [In the formula, * indicates an optically active substance, and R indicates a hydrogen atom or a hydroxyl group.] The salts of the compounds represented by formula (II), formula (IV'), formula (IV'-a), and formula (IV'-b), and the compounds represented by formula (VI), formula (VI'), formula (VII), formula (VII'), formula (VIII), and formula (VIII'), which are salt-form compounds, may be prepared by producing the corresponding sulfide-form compounds as free compounds by oxidation reaction, and then converting them into salt-form compounds. Those skilled in the art can appropriately convert the free-form compounds into any of the salt forms exemplified above to prepare the salt-form compounds.

[0085] The compounds represented by formula (I), formula (II), formula (III), formula (III'), formula (IV), formula (IV'), formula (IV'-a), and formula (IV'-b) or salts thereof, and the compounds represented by formula (VI), formula (VI'), formula (VII), formula (VII'), formula (VIII) and formula (VIII') in the form of salts may be solvates (e.g., hydrates, ethanolates, etc.) or non-solvates (e.g., non-hydrates, etc.). Both solvates and non-solvates are included in the compounds represented by formula (I), formula (II), formula (III), formula (III'), formula (IV), formula (IV'), formula (IV'-a), formula (IV'-b), formula (VI), formula (VI'), formula (VII), formula (VII'), formula (VIII) or formula (VIII').

[0086] Among the above compounds, compounds labeled with isotopes or the like are also encompassed in the compounds represented by formula (I), (II), (III), (III'), (IV), (IV'), (IV'-a), (IV'-b), (VI), (VI'), (VII), (VII'), (VIII) or (VIII'). In the above compound 1 H 2 Deuterium converted to H(D) is also encompassed in the compounds represented by formula (I), (II), (III), (III'), (IV), (IV'), (IV'-a), (IV'-b), (VI), (VI'), (VII), (VII'), (VIII) or (VIII').

[0087] In the compounds represented by formula (Va) and formula (Vb), which are diol compounds, R 1 is optionally substituted C 2-6 It represents an alkyl group or benzyl. "Optionally substituted C 2-6 The alkyl group may be, for example, C which may have a substituent selected from the following substituent group A. 2-6 Examples of such groups include alkyl groups.

[0088] [Substituent group A] (1) a halogen atom, (2) a nitro group, (3) a cyano group, (4) an oxo group, (5) a hydroxy group, (6) Optionally halogenated C 1-6 Alkoxy groups, (7) C 6-14 Aryloxy groups (e.g., phenoxy, naphthoxy), (8) C 7-16 aralkyloxy groups (e.g., benzyloxy), (9) 5- to 14-membered aromatic heterocyclyloxy group (e.g., pyridyloxy), (10) 3- to 14-membered non-aromatic heterocyclic oxy groups (e.g., morpholinyloxy, piperidinyloxy), (11) C 1-6 Alkyl-carbonyloxy groups (e.g., acetoxy, propanoyloxy), (12) C 6-14 Aryl-carbonyloxy groups (e.g., benzoyloxy, 1-naphthoyloxy, 2-naphthoyloxy), (13) C 1-6 Alkoxy-carbonyloxy group (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy), (14) mono- or di-C 1-6 Alkyl-carbamoyloxy groups (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, dimethylcarbamoyloxy, diethylcarbamoyloxy); (15) C 6-14 Aryl-carbamoyloxy groups (e.g., phenylcarbamoyloxy, naphthylcarbamoyloxy); (16) a 5- to 14-membered aromatic heterocyclylcarbonyloxy group (e.g., nicotinoyloxy), (17) a 3- to 14-membered non-aromatic heterocyclylcarbonyloxy group (e.g., morpholinylcarbonyloxy, piperidinylcarbonyloxy), (18) Optionally halogenated C 1-6 Alkylsulfonyloxy groups (e.g., methylsulfonyloxy, trifluoromethylsulfonyloxy), (19)C 1-6 C optionally substituted with an alkyl group 6-14 Arylsulfonyloxy groups (e.g., phenylsulfonyloxy, toluenesulfonyloxy), (20) Optionally halogenated C 1-6 Alkylthio groups, (21) a 5- to 14-membered aromatic heterocyclic group, (22) a 3- to 14-membered non-aromatic heterocyclic group, (23) a formyl group, (24) a carboxy group, (25) Optionally halogenated C 1-6 Alkyl-carbonyl groups, (26)C 6-14 Aryl-carbonyl groups, (27) a 5- to 14-membered aromatic heterocyclic carbonyl group, (28) a 3- to 14-membered non-aromatic heterocyclic carbonyl group, (29)C 1-6 Alkoxy-carbonyl groups, (30)C 6-14 Aryloxy-carbonyl groups (e.g., phenyloxycarbonyl, 1-naphthyloxycarbonyl, 2-naphthyloxycarbonyl), (31)C 7-16 aralkyloxy-carbonyl groups (e.g., benzyloxycarbonyl, phenethyloxycarbonyl); (32) a carbamoyl group, (33) a thiocarbamoyl group, (34) mono- or di-C 1-6 Alkyl-carbamoyl groups, (35)C 6-14 Aryl-carbamoyl groups (e.g., phenylcarbamoyl), (36) 5- to 14-membered aromatic heterocyclic carbamoyl groups (e.g., pyridylcarbamoyl, thienylcarbamoyl), (37) 3- to 14-membered non-aromatic heterocyclic carbamoyl groups (e.g., morpholinylcarbamoyl, piperidinylcarbamoyl), (38) Optionally halogenated C 1-6 Alkylsulfonyl groups, (39)C 6-14 Arylsulfonyl groups, (40) 5- to 14-membered aromatic heterocyclylsulfonyl groups (e.g., pyridylsulfonyl, thienylsulfonyl), (41) Optionally halogenated C 1-6 an alkylsulfinyl group, (42)C 6-14 Arylsulfinyl groups (e.g., phenylsulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfinyl), (43) 5- to 14-membered aromatic heterocyclylsulfinyl groups (e.g., pyridylsulfinyl, thienylsulfinyl), (44) an amino group, (45) mono- or di-C 1-6 alkylamino groups (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, N-ethyl-N-methylamino); (46) mono- or di-C 6-14 Arylamino groups (e.g., phenylamino), (47) 5- to 14-membered aromatic heterocyclic amino group (e.g., pyridylamino), (48)C 7-16 aralkylamino groups (e.g., benzylamino), (49) a formylamino group, (50)C 1-6 Alkyl-carbonylamino groups (e.g., acetylamino, propanoylamino, butanoylamino), (51)(C 1-6 Alkyl)(C 1-6 alkyl-carbonyl)amino groups (e.g., N-acetyl-N-methylamino); (52)C 6-14 Aryl-carbonylamino groups (e.g., phenylcarbonylamino, naphthylcarbonylamino); (53)C 1-6 alkoxycarbonylamino groups (e.g., methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino, tert-butoxycarbonylamino); (54)C 7-16 aralkyloxy-carbonylamino group (e.g., benzyloxycarbonylamino), (55)C 1-6 Alkylsulfonylamino groups (e.g., methylsulfonylamino, ethylsulfonylamino), (56)C 1-6 C optionally substituted with an alkyl group 6-14 Arylsulfonylamino groups (e.g., phenylsulfonylamino, toluenesulfonylamino), (57) Optionally halogenated C 1-6 Alkyl groups, (58)C 2-6 Alkenyl groups, (59)C 2-6 Alkynyl groups, (60)C 3-10 Cycloalkyl groups, (61)C 3-10 Cycloalkenyl groups, and (62)C 6-14 Aryl groups.

[0089] "Optionally substituted C 2-6 The number of the above-mentioned substituents in the "alkyl group" is, for example, 1 to 5, preferably 1 to 3. When the number of the substituents is 2 or more, the respective substituents may be the same or different.

[0090] R 1 is preferably unsubstituted C 2-6 The alkyl groups are and benzyl, more preferably ethyl, isopropyl, tert-butyl, and benzyl, and most preferably isopropyl.

[0091] The most preferred embodiment of the compound of formula (Va) is (R,R)-diisopropyl tartrate. The most preferred embodiment of the compound of formula (Vb) is (S,S)-diisopropyl tartrate.

[0092] Hereinafter, a method for producing an optically active 1,4-benzothiazepine-1-oxide derivative (a compound represented by formula (II)) or a salt thereof will be described in detail. The optically active compound of the compound represented by formula (II) or a salt thereof can be produced by the production method shown in the following reaction scheme. Reaction scheme:

[0093] [ka]

[0094] [In the formula, * represents an optically active substance, and X represents a hydrogen atom or a substituent.]

[0095] The reagents and conditions used in the above production method are described in detail below. The above-mentioned production method is a method for producing an optically active substance of a compound represented by formula (II) or a salt thereof by reacting a compound represented by formula (I) or a salt thereof with a titanium compound, a chiral diol compound, reactants including water, and an oxidizing agent in a solvent.

[0096] The chiral diol ligand may be a chiral diol compound of any structure as long as it functions as a reactant in the oxidation reaction of the present invention. Examples of the chiral diol include the optically active compounds shown below.

[0097] [ka]

[0098] [ka]

[0099] [ka]

[0100] [In the formula, R 1is optionally substituted C 2-6 It represents an alkyl group or benzyl.

[0101] The chiral diol compound is preferably tartrate diol. More preferably, it is a chiral tartrate diol represented by the above formula (Va) and formula (Vb). More preferred examples include (R,R)-diethyl tartrate, (S,S)-diethyl tartrate, (R,R)-diisopropyl tartrate, (S,S)-diisopropyl tartrate, (R,R)-di-tert-butyl tartrate, (S,S)-di-tert-butyl tartrate, (R,R)-dibenzyl tartrate, and (S,S)-dibenzyl tartrate. Most preferred is (R,R)-diisopropyl tartrate or (S,S)-diisopropyl tartrate, particularly (S,S)-diisopropyl tartrate.

[0102] As shown in the examples described later, when an (R,R)-tartrate diol compound is used, the (S) isomer of compound (II) is produced in excess, and when an (S,S)-tartrate diol compound is used, the (R) isomer of compound (II) is produced in excess. The same is true for the production of the compounds represented by formula (IV), formula (IV'), formula (VI), formula (VI'), formula (VII), formula (VII'), formula (VIII) and formula (VIII'). When a reactant containing an (R,R)-tartaric acid diol compound is used, the reaction product of the (S) form is produced in excess (preferentially), and conversely, when a reactant containing an (S,S)-tartaric acid diol compound is used, the reaction product of the (R) form is produced in excess (preferentially). Therefore, the production of the (S) form or the (R) form can be controlled by selecting the optical isomer of the chiral tartaric acid diol.

[0103] The same control is applied to the production of the compound represented by formula (IV'-a) in the (R) form and the production of the compound represented by formula (IV'-b) in the (S) form. In the former case, an (S,S)-tartrate diol compound such as the compound represented by formula (Va) is preferably used. In the latter case, an (R,R)-tartrate diol compound such as the compound represented by formula (Vb) is preferably used.

[0104] The reactant may be composed of a titanium compound, an organometallic complex containing the chiral diol compound, and water. The organometallic complex can be isolated or purified by known means (e.g., concentration, solvent extraction, fractional distillation, crystallization, recrystallization, chromatography) from a chiral diol compound serving as a ligand and a titanium-containing titanium compound serving as a metal source. The organometallic complex may be prepared by adding "another complex containing a titanium compound as a metal source" and "a chiral diol ligand" to a vessel. When preparing an organometallic complex by adding "another complex containing a titanium compound as a metal source" and "a chiral diol ligand" to a vessel, the "ligand" is added in a molar ratio of 1 to 100 times the theoretical amount required to constitute the organometallic complex. Preferably, 1 to 5 times, more preferably 1.01 to 2.02 times is used.

[0105] The reactant does not have to be an isolated or purified organometallic complex. One embodiment of the reactant is defined as a combination of a titanium compound, a chiral diol compound, and water, and the combination is added to a reaction system containing a solvent to exert its action as a reactant, thereby achieving the oxidation reaction of the present invention. Even when an isolated or purified organometallic complex is not used, the preferred molar ratio of the titanium compound to the chiral diol ligand is the same as above, and is in the range of 1:1 to 1:100. The molar ratio is more preferably 1:1 to 1:5, and further preferably 1:1.01 to 1:2.02. One example is an embodiment in which the titanium compound and the chiral diol ligand are used in a molar ratio of 1:2.

[0106] The titanium compound may be of any structure as long as it functions as a reactant in the oxidation reaction of the present invention. A preferred example of the titanium compound is titanium tetraisopropoxide.

[0107] As described above, the reactant contains the titanium compound and the chiral diol compound as well as water. Any amount of water can be used as the reactant as long as the reaction of the present invention proceeds. The amount of water used as the reactant is preferably in the range of 0.1:1 to 10:1 in terms of molar ratio to the titanium compound. The preferred molar ratio of water:titanium compound is 0.3:1 to 3:1, and the more preferred molar ratio is 0.5:1 to 2:1. The more preferred molar ratio range is water:titanium compound=1:1 to 1.3:1.

[0108] Examples of the oxidizing agent include potassium hypochlorite, sodium hypochlorite, tert-butyl hypochlorite, potassium hypobromite, sodium hypobromite, potassium hypoiodite, sodium hypoiodite, tert-butyl hydroperoxide, cumene hydroperoxide, potassium peroxymonosulfate (Oxone), metachlorobenzoic acid, and iodosylbenzene. An aqueous solution of tert-butyl hydroperoxide or cumene hydroperoxide is more preferred, and cumene hydroperoxide is most preferred. The oxidizing agent may be added to the reaction system by itself, or may be added to the reaction system in the form of a solution such as an aqueous solution.

[0109] The compounds serving as substrates for the reaction, i.e., the compounds represented by formula (I), formula (III) and formula (III') or salts thereof, can be synthesized by methods described in existing documents, such as Patent Document 1, Patent Document 2 and Patent Document 3.

[0110] The reaction of the present invention shown above is carried out in a solvent. Such a solvent is not particularly limited as long as it solubilizes the raw material compound, the organometallic complex, and the additives without inhibiting the reaction. For example, ethers such as diethyl ether, diisopropyl ether, tert-butyl methyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, methyltetrahydrofuran, 1,2-dimethoxyethane, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, and anisole; alcohols such as ethanol, n-propanol, isopropyl alcohol, n-butanol, 2-butanol, tert-butyl alcohol, 3-methyl-1-butanol, 2-methyl-1-propanol, 1-pentanol, benzyl alcohol, 2-methoxyethanol, 2-ethoxyethanol, and ethylene glycol; aromatic hydrocarbons such as benzene, toluene, xylene, cumene, and chlorobenzene; hexane, heptane, pentane, cyclohexane, Saturated hydrocarbons such as methylcyclohexane, isooctane, and petroleum ether; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, formamide, hexamethylphosphoramide, N-methylpyrrolidone, and 1,3-dimethyl-2-imidazolidinone; halogenated hydrocarbons such as chloroform, dichloromethane, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; sulfoxides such as dimethyl sulfoxide; sulfones such as dimethyl sulfone and sulfolane; ketones such as acetone, ethyl methyl ketone, methyl isopropyl ketone, and methyl butyl ketone; esters such as ethyl acetate, isopropyl acetate, n-propyl acetate, n-butyl acetate, isobutyl acetate, methyl acetate, and ethyl formate; nitromethane; and water are used. These solvents may be mixed in an appropriate ratio. Preferred examples of the solvent are toluene, chloroform, and ethyl acetate. Of these, toluene is particularly preferred.

[0111] The amount of the solvent used is appropriately determined depending on the solubility of the compound that is the substrate of the reaction, i.e., the compounds represented by formula (I), formula (III) and formula (III') or their salts. For example, when toluene is used as the solvent, the reaction can be carried out in a solvent that is 100 times or more by weight of the substrate compound or its salt, from a state close to no solvent. It is usually preferable to use a solvent in an amount of about 2 to about 100 times by weight of the substrate compound or its salt.

[0112] In one embodiment of the method of the present invention, a titanium compound (e.g., titanium tetraisopropoxide) and a chiral diol ligand (e.g., compound (Va) or compound (Vb)) are added to a vessel containing a solvent prior to the oxidation reaction. Water used as a reactant is usually added after the above addition, as described below. However, the addition of water may be carried out simultaneously with or prior to the above addition.

[0113] The titanium compound (e.g., titanium isopropoxide) is used in an amount of 0.01 to 10 mol, preferably 0.1 to 2 mol, and more preferably 0.5 to 1.5 mol, relative to the substrate (the compound represented by formula (I), formula (III) or formula (III') or a salt thereof).

[0114] The reaction system can be constructed as follows. A substrate (a compound represented by formula (I), formula (III) or formula (III') or a salt thereof) and water are added to a solution containing a titanium compound, a chiral diol ligand, and a solvent. This addition is preferably carried out before the addition of an oxidizing agent. The mixed solution may be heated prior to the addition of an oxidizing agent. The mixed solution is heated to 40 to 70°C or 50 to 55°C. Examples of the heating time are 0.1 to 3 hours and 0.5 to 1.2 hours.

[0115] Regardless of whether a heating operation is performed or not, if the temperature of the mixed solution is higher than a predetermined reaction temperature, the mixed solution is cooled to a desired reaction temperature. After cooling, an oxidizing agent is added to start the oxidation reaction. The reaction temperature is -60°C or higher and 20°C or lower. Preferably, it is -30°C or higher and lower than 0°C. More preferably, it is -30°C or higher and -10°C or lower. Even more preferably, it is -30°C or higher and -20°C or lower. The reaction time can be appropriately determined depending on the degree of progress of the reaction, but is usually 2 hours or higher and 80 hours or lower. Preferably, it is 10 hours or higher and 30 hours or lower.

[0116] The amount of the oxidizing agent used is 0.50 to 4.00 mol, more preferably 0.95 to 2.02 mol, relative to the substrate (the compound represented by formula (I), formula (III) or formula (III') or a salt thereof).

[0117] The reaction can be carried out under air at normal pressure. Alternatively, the air may be replaced with an inert gas by gas exchange, and the reaction may be carried out under an inert gas atmosphere. Examples of the inert gas include nitrogen gas and argon gas. Preferably, argon gas is used.

[0118] When the substrate is a salt with an acidic substance, a base (e.g., diisopropylethylamine, triethylamine, pyridine) may be added in an amount of 1.0 to 1.3 moles relative to the substrate. However, the method of the present invention can generally achieve an asymmetric oxidation reaction with high conversion rate, high selectivity, and / or high optical purity (high enantioselectivity) without adding a base such as diisopropylethylamine.

[0119] The conversion rate ((total oxides / (residual substrate+total oxides);%) by the method of the present invention is 50% or more, preferably 70% or more, and more preferably 90% or more. The selectivity ((monoxides / total oxides);%) according to the method of the present invention is 70% or more, preferably 90% or more, and more preferably 95% or more. The optical purity (absolute value of enantiomeric excess; %ee) achieved by the method of the present invention is 50% or more, preferably 70% or more, and more preferably 90% or more. Here, the total oxides means the sum of the oxides of the monoxide and the oxides of the dioxide corresponding to the substrate in the sulfide form. The amounts of the remaining substrate, the oxides of the monoxide, and the oxides of the dioxide are determined by measuring the area after separation by HPLC. In measuring the enantiomeric excess, the amounts of the oxides of the (R) and (S) monoxide forms can be separated and identified by HPLC according to the method described in Patent Document 1 or a method based thereon. In the examples described later, the enantiomeric excess is calculated so that a + value is given when the (R) form is preferentially produced and a - value is given when the (S) form is preferentially produced, and the results are shown.

[0120] The reaction product obtained in this reaction (the optically active compound represented by Formula (II), Formula (IV), Formula (IV'), Formula (IV'-a) and Formula (IV'-b) or a salt thereof) may be purified by known means (e.g., fractional recrystallization method, chiral column method, diastereomeric salt method). In order to obtain a reaction product with high optical purity (optically active compounds or salts thereof represented by formula (II), formula (IV'-a) and formula (IV'-b)), the product can be purified by fractional recrystallization or diastereomeric salt method after the oxidation reaction. Among them, crystallization of a diastereomeric salt with optically active mandelic acid is preferable. When the reaction product is the (R) form, crystallization using mandelic acid in the (R) form is preferable, and when the reaction product is the (S) form, crystallization using mandelic acid in the (S) form is preferable. More specifically, the reaction solution after the completion of the oxidation reaction is subjected to acid-base extraction, and then (R)-mandelic acid (or (S)-mandelic acid) is added in a solvent to crystallize the mandelic acid salt of the optically active compound. Examples of the acid used for the acid-base extraction include citric acid and hydrochloric acid. Examples of the base include potassium carbonate. After the addition of the acid and the base are performed in sequence, an organic solvent (e.g., tetrahydrofuran, toluene, or a mixture thereof) is added to extract the reaction product of the oxidation reaction. Crystallization is preferably carried out after solvent exchange after extraction. The solvent used during crystallization may be ethyl acetate, isopropyl acetate, acetone, methyl ethyl ketone, methyl isobutyl ketone, cyclopentyl methyl ether, isopropanol, tetrahydrofuran, acetonitrile, ethanol, toluene, etc. Preferred examples of the solvent include ethyl acetate, acetone, toluene, tetrahydrofuran, and ethanol, and a particularly preferred example is acetone.

[0121] The (R)-mandelic acid salt of the compound represented by formula (IV'-a) can be prepared as stable crystals that do not deliquesce even in air, as described in the Examples below.

[0122] Salts of the compounds represented by formula (II), formula (IV), formula (IV'), formula (IV'-a), and formula (IV'-b) can be formed by reacting the free compounds with an acid (p-toluenesulfonic acid, (R)-mandelic acid, etc.) in a solvent (e.g., tetrahydrofuran, ethyl acetate, acetonitrile, or any mixture of two or more of these). The hydrochloride of the compound can also be formed by salt exchange using a compound in a salt form other than hydrochloride as a material. For example, a solution containing HCl (e.g., a solution of hydrochloric acid in ethyl acetate, a solution of hydrochloric acid in methanol, a solution of hydrochloric acid in methanol) can be added to a solution or slurry containing a salt of the compound (fumarate, mandelate, p-toluenesulfonate, methanesulfonate, etc.) to obtain the hydrochloride of the compound represented by formula (II), formula (IV), formula (IV'), formula (IV'-a), and formula (IV'-b). A preferred example of the salt of the compound as a material is (R)-mandelate. The solution or slurry containing the salt of the compound preferably contains tetrahydrofuran, ethyl acetate, acetonitrile, or any mixture of two or more of these as a solvent. More preferably, it is ethyl acetate, a mixture of ethyl acetate and acetonitrile, or a mixture of tetrahydrofuran and acetonitrile, and particularly preferably a mixture of tetrahydrofuran and acetonitrile. A preferred example of the solution containing HCl is a solution of hydrochloric acid in ethyl acetate (HCl / EtOAc). The salt of the compound as the raw material and HCl in the HCl-containing solution may be used in any ratio, but preferably in an equivalent ratio range of 1:1.1 to 1:1.5. The addition may be carried out under any temperature environment, but is preferably carried out under room temperature environment. The hydrochloride of the compound can be precipitated by adding and mixing for a certain period of time. After mixing at room temperature for a certain period of time, it may be cooled (for example, to 0°C). The precipitate thus separated out can be washed with a cold solvent (eg, ethyl acetate, tetrahydrofuran, acetone) and then dried under reduced pressure to isolate the compound as a crystal of its hydrochloride salt. EXAMPLES

[0123] The present invention will be further explained in detail by the following test examples and examples. However, these examples are merely illustrative and do not limit the present invention, and may be modified without departing from the scope of the present invention.

[0124] In the following Test Examples and Examples, "room temperature" generally refers to about 10°C to about 35°C. Chemical yields are given as isolated yields (mol / mol%) or as yields obtained by high performance liquid chromatography. The optical purity (asymmetric yield) of the optically active substance was evaluated in terms of the enantiomeric excess (% ee), which was calculated according to the following formula: Enantiomeric excess (% ee) = 100 × [(R) - (S)] / [(R) + (S)] (wherein, (R) and (S) represent the areas of each enantiomer in high performance liquid chromatography.) The amount of solvent used in chromatography is expressed as volume percent, and the amount of other substances used is expressed as weight percent. In the analysis results of the proton NMR spectrum, data is not given for peaks such as OH and NH protons that are broad and cannot be confirmed.

[0125] Other abbreviations used in the text have the following meanings: s: singlet d: doublet t: triplet q : Quartet m : multiplet br: broad J: Coupling constant Hz: Hertz CDCl3: deuterated chloroform DMSO-d6: deuterated dimethyl sulfoxide CD3OD: deuterated methanol 1 H-NMR: Proton nuclear magnetic resonance 13 C-NMR: 13 C nuclear magnetic resonance

[0126] In the following examples, nuclear magnetic resonance spectra (NMR) were measured under the following conditions. 1 H nuclear magnetic resonance spectrum (1 H NMR): Bruker AVANCE 500 (500 MHz), internal standard: tetramethylsilane 13 C nuclear magnetic resonance spectrum ( 13 C NMR): BRUKER AVANCE 500 (125MHz), internal standard: CDCl3

[0127] In the following test examples, dynamic vapor sorption curves (DVS) were measured using a DVS Adventure 1 manufactured by Surface Measurement Systems.

[0128] Example 1 Synthesis of 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide (2)

[0129] [ka]

[0130] A solvent (toluene or dichloromethane) (1.5 mL), (R,R)-diethyl tartrate (0.0514 mL), and titanium tetraisopropoxide (0.0444 mL) were added to a test tube and stirred at room temperature for 3 minutes or more. Then, water (0.0027 mL) was added and stirred at room temperature for 3 minutes or more. Then, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.0637 g) or fumarate salt of (1) (0.0853 g) was added and stirred at room temperature for 20 minutes. The reaction solution was cooled, and cumene hydroperoxide (2 equivalents relative to (1)) was added at -20°C, and stirred at -20°C for 21 hours. Based on the area obtained by HPLC, the conversion rate to (2), the selectivity, and the enantiomeric excess of ((R)-2) were calculated. Conversion rate = ((2) + (3)) / ((1) + (2) + (3)) Selection rate = ((2)) / ((2)+(3)) In the above two formulas, (2) represents the total value of (R)-2 and (S)-2. The enantiomeric excess (% ee) of ((R)-2) was calculated as above by 100 × [((R)-2)-((S)-2)] / [((R)-2)+((S)-2)]. The results are shown in Table 1. In the table, negative enantiomeric excess values ​​indicate that ((S)-2) was the main product.

[0131] High performance liquid chromatography analysis conditions (area percentage, optical purity) Column: CHIRALPAK IC (Daicel Chemical Industries, Ltd.), 4.6*250 mm UV detection wavelength: 245 nm Mobile phase: acetonitrile for high performance liquid chromatography / methanol / diethylamine = 900 / 100 / 1 Flow rate: 1.0 mL / min Column temperature: 40 °C Retention time: 5.0 min. (1), 5.6 min. (3), 9.8 min. ((R)-2), 12.5 min. ((S)-2) It has been confirmed that ((R)-2) is the same compound as the first optical isomer component in Patent Document 1, and ((S)-2) is the same compound as the second optical isomer component in Patent Document 1.

[0132] [Table 1]

[0133] Regardless of whether the substrate (1) was in the free form or in the form of a fumarate salt, the monoxide compound (2) was produced with high selectivity. In this example, in which (R,R)-diethyl tartrate was used as the chiral diol compound, the (S)-monoxide compound ((S)-2) was produced as the main product. Although asymmetric synthesis could be carried out using either toluene or dichloromethane as a solvent, toluene gave a higher optical purity under the conditions of this example.

[0134] Example 2 Synthesis of 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide (2)

[0135] [ka]

[0136] Toluene (1.5 mL), (R,R)-diethyl tartrate (0.0514 mL), and titanium tetraisopropoxide (0.0444 mL) were added to a test tube and stirred at room temperature for 3 minutes or more. Water (0.0027 mL) was then added and stirred at room temperature for 3 minutes or more. 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.0637 g) was then added and stirred at room temperature for 20 minutes. After the reaction solution was brought to a specified temperature, an oxidizing agent (2 equivalents relative to (1)) was added and stirred at the same temperature for 21 hours. The conversion rate to (2) and the enantiomeric excess of ((R)-2) were calculated by HPLC.

[0137] The results are shown in Table 2. In the table, negative enantiomeric excess values ​​indicate that ((S)-2) was the main product.

[0138] The high performance liquid chromatography analysis conditions (area percentage, optical purity) were the same as in Example 1.

[0139] [Table 2]

[0140] When a 70% aqueous solution of t-butyl hydroperoxide was used as the oxidizing agent, an asymmetric synthesis reaction was confirmed in which ((S)-2) was the main product. At a reaction temperature of -20°C, higher optical purity was observed than at 0°C or room temperature. When a 30% aqueous solution of hydrogen peroxide was used as the oxidizing agent, the oxide obtained was almost entirely dioxide compound (3).

[0141] Example 3 Synthesis of 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide (2)

[0142] [ka]

[0143] To a 20 mL Schlenk flask, toluene (1.5 mL), a chiral diol compound (ligand) (2 equivalents relative to Ti(Oi-Pr)4), and titanium tetraisopropoxide (a specified amount relative to (1)) were added under an argon atmosphere, and the mixture was stirred at room temperature for 3 minutes or more. Water (0.0027 mL) was then added, and the mixture was stirred at room temperature for 3 minutes or more. 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.0637 g) was then added, and the mixture was stirred at room temperature for 20 minutes. The reaction solution was cooled as necessary, and then cumene hydroperoxide or 70% t-butyl hydroperoxide aqueous solution was added as an oxidizing agent (2 equivalents relative to (1)) at a specified temperature, and the mixture was stirred at the same temperature for 21 hours. The conversion rate to (2) and the enantiomeric excess of ((R)-2) were calculated by HPLC.

[0144] The results are shown in Table 3. In the table, negative values ​​for the enantiomeric excess indicate that ((S)-2) was the main product. The structural formulas of the chiral diol compounds (ligands) used, (R,R)-diethyl tartrate, (S,S)-dimethyl tartrate, (S,S)-diisopropyl tartrate, (R,R)-di-t-butyl tartrate, (R,R)-dibenzyl tartrate, (R,R)-hydroxybenzoin, (R)-binaphthol, and (S)-dibromobinaphthol, are also shown below.

[0145] The high performance liquid chromatography analysis conditions (area percentage, optical purity) were the same as in Example 1.

[0146] [Table 3]

[0147] [ka]

[0148] Under the above conditions, when (S,S)-dimethyl tartrate, (R,R)-hydroxybenzoin, (R)-binaphthol, or (S)-dibromobinaphthol was used as the chiral diol compound (ligand), no sufficient oxidation reaction to the monooxide compound was observed. On the other hand, when (R,R)-diethyl tartrate or (R,R)-dibenzyl tartrate was used as the chiral diol compound (ligand), an asymmetric synthesis reaction was achieved with ((S)-2) as the main product, and when (S,S)-diisopropyl tartrate was used, an asymmetric synthesis reaction was achieved with ((R)-2) as the main product. Under these conditions, both the conversion rate and selectivity were sufficiently high.

[0149] Example 4 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0150] [ka]

[0151] In a 20 mL Schlenk flask, solvent (1.5 mL), (S,S)-diisopropyl tartrate (0.1361 mL), and titanium tetraisopropoxide (0.0962 mL) were added under argon atmosphere and stirred at room temperature for 3 minutes or more. Water (0.0059 mL) was then added and stirred at room temperature for 3 minutes or more. 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.1380 g) was then added and stirred at room temperature for 20 minutes. After cooling the reaction solution, cumene hydroperoxide (0.1189 mL) was added at -20°C and stirred at the same temperature for 21 hours. The conversion rate to (2) and the enantiomeric excess of ((R)-2) were calculated by HPLC.

[0152] The solvent used was any one of toluene, dichloromethane, chloroform, acetonitrile, tetrahydrofuran, ethyl acetate, methanol, ethanol, and isopropyl alcohol. The results are shown in Table 4. The high performance liquid chromatography analysis conditions (area percentage, optical purity) were the same as in Example 1.

[0153] [Table 4]

[0154] When a solvent other than methanol was used, a sufficiently high conversion rate was obtained. In particular, when toluene, chloroform, and ethyl acetate were used, high values ​​were obtained for the selectivity and optical purity, and the optical isomer ((R)-2) was produced in good yield.

[0155] Example 5 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0156] [ka]

[0157] To a 20 mL Schlenk flask, toluene (1.5 mL), (S,S)-diisopropyl tartrate (0.1361 mL), and titanium tetraisopropoxide (0.0962 mL) were added under an argon atmosphere and stirred at room temperature for 3 minutes. Water (0.0059 mL) was then added and stirred at room temperature for 3 minutes. 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.1380 g) was then added, and the mixture was heated to 50°C and stirred for 2 hours. The reaction solution was cooled, and then cumene hydroperoxide (0.1189 mL) was added at -20°C and stirred at the same temperature for 3 hours. The results were HPLC conversion rate: 97%, (2) / (3) selectivity: 93%, and enantiomeric excess: 91.2% ee. In this example, which used (S,S)-diisopropyl tartrate as the chiral diol compound, cumene hydroperoxide as the oxidizing agent, and toluene as the solvent, a reaction with extremely high conversion rate and selectivity and excellent optical purity was achieved, and the optical isomer ((R)-2) was obtained in high yield.

[0158] Example 6 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0159] [ka]

[0160] To a 20 mL Schlenk flask, toluene (1.5 mL), (S,S)-diisopropyl tartrate (0.1361 mL), and titanium tetraisopropoxide (0.0962 mL) were added under an argon atmosphere and stirred at room temperature for 3 minutes. Water (0.0059 mL) was then added and stirred at room temperature for 3 minutes. 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.1380 g) was then added, and the mixture was heated to 50°C and stirred for 2 hours. The reaction solution was cooled, and then cumene hydroperoxide (0.1189 mL) was added at -20°C and stirred at the same temperature for 21 hours. The results were HPLC conversion: 100%, selectivity for (2) / (3): 66%, and enantiomeric excess: 96.1% ee. Comparing with the results of Example 5, it became clear that under the conditions of these Examples, a reaction time of 3 hours was sufficient.

[0161] Example 7 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0162] [ka]

[0163] In a 20 mL Schlenk flask, toluene (1.5 mL), (S,S)-diisopropyl tartrate (0.1361 mL), and 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.1380 g) were added under an argon atmosphere, and the mixture was stirred at room temperature for 3 minutes. Then, titanium tetraisopropoxide (0.0962 mL) was added, and the mixture was stirred at room temperature for 3 minutes. After adding water (0.0059 mL), the mixture was heated to 50°C and stirred for 2 hours. After cooling the reaction solution, cumene hydroperoxide (0.1189 mL) was added at -20°C, and the mixture was stirred at the same temperature for 3 hours. The results were HPLC conversion: 96%, selectivity for (2) / (3): 95%, and enantiomeric excess: 92.2% ee. Although the order of addition of the substrate and titanium compound is different between Example 5 and this Example, in both Examples, the conversion rate and selectivity were both extremely high, and reactions with excellent optical purity were achieved, and the ((R)-2) optical isomer was obtained in high yield.

[0164] Example 8 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0165] [ka]

[0166] In a 20 mL Schlenk flask, toluene (1.5 mL), (S,S)-diisopropyl tartrate (0.1361 mL), and titanium tetraisopropoxide (0.0962 mL) were added under an argon atmosphere, and the mixture was stirred at room temperature for 3 minutes. Then, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.1380 g) was added, and the mixture was stirred at room temperature for 3 minutes. After adding water (0.0059 mL), the mixture was heated to 50°C and stirred for 2 hours. After cooling the reaction solution, cumene hydroperoxide (0.1189 mL) was added at -20°C, and the mixture was stirred at the same temperature for 3 hours. The results were HPLC conversion: 95%, selectivity for (2) / (3): 95%, and enantiomeric excess: 91.8% ee. Although the order of addition of the substrate and water differs between Example 5 and this Example, in both Examples, the conversion rate and selectivity were both extremely high, and reactions with excellent optical purity were achieved, resulting in the production of the ((R)-2) optical isomer in high yield.

[0167] Example 9 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0168] [ka]

[0169] To a 20 mL Schlenk flask, toluene (1.5 mL), (S,S)-diisopropyl tartrate (0.1361 mL), and titanium tetraisopropoxide (0.0962 mL) were added under an argon atmosphere, and the mixture was stirred at room temperature for 3 minutes. Then, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) hydrochloride (0.1500 g) was added, and the mixture was stirred at room temperature for 3 minutes. After adding water (0.0059 mL), the mixture was heated to 50°C and stirred for 2 hours. After cooling the reaction solution, cumene hydroperoxide (0.1189 mL) was added at -20°C, and the mixture was stirred at the same temperature for 3 hours. The results were HPLC conversion: 70%, selectivity for (2) / (3): 96%, and enantiomeric excess: 57.0% ee. Even when the salt of (1) was used as the substrate, sufficient conversion and selectivity were obtained, and the optically active monoxide compound ((R)-2) was produced with high optical purity.

[0170] Example 10 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0171] [ka]

[0172] To a 20 mL Schlenk flask, toluene (1.5 mL), (S,S)-diisopropyl tartrate (0.1361 mL), and titanium tetraisopropoxide (0.0962 mL) were added under an argon atmosphere, and the mixture was stirred at room temperature for 3 minutes. Then, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) hydrochloride (0.150 g) and a base (1.0-1.3 equivalents per 1) were added, and the mixture was stirred at room temperature for 3 minutes. After adding water (0.0059 mL), the mixture was heated to 50°C and stirred for 2 hours. After cooling the reaction solution, cumene hydroperoxide (0.1189 mL) was added at -20°C, and the mixture was stirred at the same temperature for 3 hours. The conversion rate to (2) and the enantiomeric excess of (R)-2 were calculated by HPLC. The results are shown in Table 5.

[0173] [Table 5]

[0174] Even when diisopropylethylamine and triethylamine were used as the base, sufficient conversion and selectivity were obtained, and the optically active monoxide compound ((R)-2) was produced with high optical purity. Even when the amount of base added was increased from 1.0 equivalent to 1.3 equivalents, the conversion rate was only slightly improved, and no significant difference was observed in the results. Comparing with the results of Example 9, when a salt form substrate was used, the addition of diisopropylethylamine or triethylamine as a base improved the optical purity. This suggests that the substrate was desalted by the base and was used in the reaction as a free form. On the other hand, the addition of pyridine as a base had almost no effect on the optical purity.

[0175] Example 11 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0176] [ka]

[0177] In a 20 mL Schlenk flask, toluene (10 mL), (S,S)-diisopropyl tartrate (0.908 mL), and titanium tetraisopropoxide (0.642 mL) were added under an argon atmosphere and stirred at room temperature for 3 minutes. Then, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.921 g) was added and stirred at room temperature for 3 minutes. After adding water (0.0390 mL), the temperature was raised to 50°C and stirred for 2 hours. After cooling the reaction solution, cumene hydroperoxide (0.397 mL) was added at -20°C and stirred at the same temperature for 99 hours. The results were HPLC conversion: 99%, selectivity for (2) / (3): 93%, and enantiomeric excess: 94.5% ee. As in Example 5, the reaction was achieved with extremely high conversion and selectivity, and excellent optical purity, giving the optical isomer ((R)-2) in high yield. A slight improvement in the conversion rate and optical purity was observed by extending the reaction time, as compared with the results of Example 5. In addition, no significant effect was observed by reducing the amount of the oxidizing agent used from 2.0 equivalents to 1.0 equivalent (equivalent to the substrate).

[0178] Example 12 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0179] [ka]

[0180] To a 300mL four-neck flask, toluene (80 mL), (S,S)-diisopropyl tartrate (8.128 g), and titanium tetraisopropoxide (5.136 mL) were added under an argon atmosphere and stirred at room temperature for 3 minutes. Then, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (7.367 g) was added and stirred at room temperature for 3 minutes. After adding water (0.312 mL), the temperature was raised to 50°C and stirred for 2 hours. After cooling the reaction solution, cumene hydroperoxide (3.301 mL) was added at -20°C and stirred at the same temperature for 22 hours. The results were HPLC conversion: 97%, selectivity for (2) / (3): 95%, and enantiomeric excess: 94.5% ee. The reaction was carried out on a larger scale than in Example 11. As in Example 5, the conversion rate and selectivity were both extremely high, and the reaction was excellent in optical purity, resulting in the production of the ((R)-2) optical isomer in high yield.

[0181] (Example 13) Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide ((R)-2)

[0182] [ka]

[0183] To a 20 mL Schlenk flask, toluene (10 mL), (S,S)-diisopropyl tartrate (0.908 mL), and titanium tetraisopropoxide (0.642 mL) were added under an argon atmosphere and stirred at room temperature for 3 minutes. Then, 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) (0.921 g) was added and stirred at room temperature for 3 minutes. After adding water (0.0390 mL), the temperature was raised to 50°C and stirred for 2 hours. After cooling the reaction solution, cumene hydroperoxide (0.377 mL) was added at -20°C and stirred at the same temperature for 22 hours. The results were HPLC conversion: 96%, selectivity for (2) / (3): 96%, and enantiomeric excess: 93.9% ee. As in Example 12, the reaction was achieved with extremely high conversion and selectivity, and excellent optical purity, giving the optical isomer ((R)-2) in high yield.

[0184] Example 14 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide (R)-mandelate

[0185] [ka]

[0186] 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) hydrochloride (8.00 g) was dissolved completely in water (64 mL) and a 1 / 1 mixed solvent of hexane / ethyl acetate (64 mL). Sodium carbonate (2.02 g) was added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, and the aqueous layer was extracted twice with a 1 / 1 mixed solvent of hexane / ethyl acetate (20 mL). All the organic layers were dried over sodium sulfate and concentrated under reduced pressure with toluene to give 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1). The inside of a 300 mL four-neck flask was depressurized and then refilled with argon gas three times. Under an argon gas atmosphere, toluene (70 mL) and (S,S)-diisopropyl tartrate (8.128 g) were added, and then titanium tetraisopropoxide (5.136 mL) was added at 27-30°C. 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) diluted with 5 mL of toluene and ultrapure water (0.312 mL) were added at 30°C. The resulting heterogeneous solution was heated to 50°C and stirred at 50-55°C for 1 hour. The resulting light yellow homogeneous reaction solution was cooled to -19°C, and cumene hydroperoxide (3.301 g) diluted with 5 mL of toluene was added dropwise at -19°C to -17°C. The resulting reaction mixture was stirred at -21°C to -19°C for 22 hours. The reaction was monitored by HPLC. 40 mL of 20% aqueous sodium thiosulfate was added and stirred at 0°C or less for 20 minutes. The organic layer was separated, and the aqueous layer was re-extracted with 32 mL of ethyl acetate. To the combined organic layers, 32 mL of 3 mol / L hydrochloric acid and 15 mL of methanol were added and stirred at room temperature for 5 minutes. The aqueous layer was separated, and the organic layer was re-extracted with 20 mL of a water / methanol = 3 / 1 mixed solvent. The aqueous layers were mixed, and 30 mL of a 3 mol / L potassium carbonate aqueous solution and a THF / toluene mixed solvent were added thereto, and stirred at room temperature for 5 minutes. The organic layer was separated, and the aqueous layer was extracted twice with 30 mL of a THF / toluene mixed solvent. The combined organic layers were dried over sodium sulfate. HPLC analysis showed that ((R)-2) was produced in the reaction mixture with a quantitative yield of 81% and 94.5% ee. After the solvent was replaced with acetone, (R)-mandelic acid (2.61 g) was added at room temperature, and then seed crystals were added, causing rapid crystallization. The mixture was stirred at room temperature for 10 minutes, cooled to 0°C, and aged for 2 hours. The crystals were collected by filtration and washed with chilled acetone. The resulting solid was dried under reduced pressure at 60 °C for 4 h to give 7.5377 g of (R)-2·mandelate in 73% yield and 98.1% ee.

[0187] High performance liquid chromatography analysis conditions (area percentage) Column: Atlantis T3 (Waters), 4.6 mm id * 100 mm, 5 m UV detection wavelength: 210 nm Mobile phase: 0.1 v / v% phosphoric acid / acetonitrile for high performance liquid chromatography = 58 / 42 Flow rate: 1.0 mL / min Column temperature: 40 °C Holding time: 1.6 min. (2), 2.1 min. (3), 3.7 min. (1)

[0188] High performance liquid chromatography analysis conditions (optical purity) Column: CHIRALPAK IC (Daicel Chemical Industries, Ltd.), 4.6 mm id * 250 mm, 5 m UV detection wavelength: 245 nm Mobile phase: acetonitrile for high performance liquid chromatography / methanol / diethylamine = 900 / 100 / 1 Flow rate: 1.0 mL / min Column temperature: 40 °C Retention time: 5.0 min. (1), 5.6 min. (3), 9.8 min. ((R)-2), 12.5 min. ((S)-2)

[0189] The results of the nuclear magnetic resonance analysis were as follows: [Compound data (R)-2·(R)-MA] 1 H NMR (500 MHz, CDCl 3,observed as two rotamers whose ratio is 50 to 50) ··1.26-1.51 (m, 2 H), 1.51-1.76 (m, 3 H), 2.23-2.99 (m, 7 H), 3.00-3.49 (m, 6 H), 3.74-3.85 (m, 1H), 3.80 (s, 0.5×3 H), 3.87 (s, 0.5×3 H), 4.15-4.75 (m, 3 H), 4.86-5.15 (m, 1 H), 4.98 (s, 1 H), 6.80 (dd, J = 8.5, 2.0 Hz, 0.5×1 H), 6.85 (dd, J = 8.5, 2.0 Hz, 0.5×1 H), 6.99 (dd, J = 6.0, 2.5 Hz, 1 H), 7.02-7.11 (m, 2 H), 7.16-7.23 (m, 1 H), 7.23-7.31 (m, 3 H), 7.31-7.39 (m, 2 H), 7.56 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 8.5 Hz, 0.5×1 H), 7.65 (d, J = 8.5 Hz, 0.5×1 H).

[0190] Example 15 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide hydrochloride

[0191] [ka]

[0192] 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) hydrochloride (5.00 g) was completely dissolved in water (40 mL) and a 1 / 1 mixed solvent of hexane / ethyl acetate (40 mL). Sodium carbonate (1.26 g) was added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, and the aqueous layer was extracted twice with a 1 / 1 mixed solvent of hexane / ethyl acetate (10 mL). All the organic layers obtained were dried over sodium sulfate and concentrated under reduced pressure with toluene to obtain 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1). The pressure in a 200 mL four-neck flask was reduced, and the flask was filled with argon gas three times. Under an argon gas atmosphere, toluene (40 mL) and (S,S)-diisopropyl tartrate (5.081 g) were added, followed by titanium tetraisopropoxide (3.082 mL) at 23-27 °C. 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (1) diluted with 5 mL of toluene and ultrapure water (0.195 mL) were added at 26-28 °C. The resulting heterogeneous solution was heated to 50 °C and stirred at 50-53 °C for 30 minutes. The resulting light yellow homogeneous reaction solution was cooled to -19 °C, and cumene hydroperoxide (2.063 g) diluted with 5 mL of toluene was added dropwise at -19 °C to -18 °C. The resulting reaction mixture was stirred at -20 °C to -19 °C for 21 hours. The reaction was monitored by HPLC. 25 mL of 20% sodium thiosulfate aqueous solution was added and stirred at 0°C or lower for 10 minutes. The organic layer was separated and the aqueous layer was re-extracted with 20 mL of ethyl acetate. 20 mL of 3 mol / L hydrochloric acid and 12.5 mL of methanol were added to the combined organic layers and stirred at room temperature for 10 minutes. The aqueous layer was separated and the organic layer was re-extracted with 10 mL of a water / methanol = 3 / 1 mixed solvent. The aqueous layers were mixed, and 22.5 mL of a 3 mol / L potassium carbonate aqueous solution and a THF / toluene mixed solvent were added thereto and stirred at room temperature for 5 minutes. The organic layer was separated and the aqueous layer was extracted twice with 15 mL of a THF / toluene mixed solvent.The combined organic layers were dried over sodium sulfate. HPLC analysis showed that (R)-2 was produced in the reaction solution with a quantitative yield of 86% and 94.6% ee. After replacing the solvent with acetone, the temperature was raised to 56°C, (R)-mandelic acid (1.65 g) was added, and the mixture was stirred at the same temperature for 1 minute. The mixture was cooled to room temperature, and the resulting crystals were further aged for 3 hours. The crystals were collected by filtration and washed with chilled acetone, and the resulting solid was dried under reduced pressure at 60°C for 2 hours to give 4.28 g of (R)-2·mandelate in 72% yield and 98.8% ee.

[0193] (R)-2·mandelate (3.00 g) was suspended in 24 mL of THF / acetonitrile=3 / 1 mixture. 1.52 mL of 4 mol / L hydrochloric acid / ethyl acetate solution was added dropwise at 22-28 °C, and the mixture was stirred at room temperature for 1 h. The mixture was cooled to 0 °C and stirred for an additional 2 h. The resulting solid was collected by filtration, washed with 16 mL of chilled THF, and dried under reduced pressure at 50 °C overnight to give 2.38 g of (R)-2·hydrochloride in 98% yield and 99.3% ee.

[0194] Example 16 Synthesis of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5--1,4-benzothiazepine-1-oxide p-toluenesulfonate (R)-4-3-[(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2-3-4-5-tetrahydro-1,4-benzothiazepine-1-oxide (0.700 g) was dissolved completely in THF (6.3 mL). p-Toluenesulfonic acid monohydrate (0.333 g) was added, and seed crystals were added, followed by stirring at room temperature for 19 hours. The mixture was cooled to 0°C and stirred for an additional hour. The resulting solid was collected by filtration, washed with 6 mL of cooled THF, and dried overnight under reduced pressure at 50°C to give 0.941 g of (R)-2·p-toluenesulfonate in 93% yield.

[0195] The results of the nuclear magnetic resonance analysis were as follows: [Compound data (R)-2·p-TsOH] 1 H NMR (500 MHz, CDCl 3, observed as two rotamers whose ratio is 56 to 44) · 1.65-1.82 (m, 4 H), 2.40 (s, 3 H), 2.47-2.71 (m, 4 H), 2.81-3.17 (m, 2 H), 3.18-3.47 (m, 6 H), 3.80 (s, 0.56×3 H), 3.89 (s, 0.44×3 H), 4.03-4.16 (m, 0.56×1 H), 4.24-4.78 (m, 0.56×2 H, 0.44×3 H), 4.97 (d, J = 14.0 Hz, 0.56×1 H), 5.21 (d, J = 16.0 Hz, 0.44×1 H), 6.70-6.92 (m, 1 H), 7.00 (m, 0.56×1 H), 7.04-7.13 (m, 2 H), 7.19-7.42 (m,0.56×6 H, 0.44×7 H), 7.57-7.67 (m, 1 H), 7.80 (d, J = 8.0 Hz, 2 H), 10.50 (BS, 0.56×1 H), 10.58 (BS, 0.44×1 H).

[0196] (Test Example 1) Hygroscopic properties test of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide salt The dynamic vapor sorption curves (DVS) of (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide hydrochloride, p-toluenesulfonate, and (R)-mandelate were measured to investigate their hygroscopic properties. As a result, deliquescence due to moisture absorption was confirmed in hydrochloric acid (Figure 1). In addition, although the p-toluenesulfonate salt absorbed less moisture than the hydrochloride salt, deliquescence was confirmed (Figure 2), whereas no moisture absorption was observed for the mandelate salt (Figure 3). [Industrial Applicability]

[0197] The (R)-4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine-1-oxide or a salt thereof produced by the method of the present invention gently increases heart rate and blood pressure and is useful as a therapeutic or preventive drug for atrial fibrillation and heart failure. Therefore, the present invention has industrial applicability in the pharmaceutical field.

Claims

1. The following formula (III) 【Chemistry 3】 [In the formula, R represents a hydrogen atom or a hydroxyl group.] or a salt thereof with a titanium compound, a chiral diol compound, a reactant containing water, and an oxidizing agent in a solvent, 【Chemistry 4】 [In the formula, * indicates that the compound is optically active, and R indicates a hydrogen atom or a hydroxyl group.] A method for producing an optically active compound represented by the formula: The titanium compound is titanium tetraisopropoxide, The chiral diol compound is selected from a tartaric acid diester represented by the following formula (Va) and a tartaric acid diester represented by the following formula (Vb): Manufacturing method: 【Chemistry 5】 [In the formula, R 1 represents an optionally substituted C 2-6 alkyl group or benzyl.] 【Chemistry 6】 [The symbols in the formula are as defined above.]

2. The method according to claim 1, wherein in formula (III) and formula (IV), R is a hydrogen atom.

3. The method according to claim 1 or 2, wherein the compound represented by formula (III) or a salt thereof is a compound represented by formula (III).

4. 3. The process according to claim 1 or 2, wherein the compound represented by formula (III) or a salt thereof is a hydrochloride, a fumarate, a mandelate or a sulfonate of the compound represented by formula (III).

5. The method according to any one of claims 1 to 4, wherein the tartrate diester represented by formula (Va) or formula (Vb) is a tartrate diester selected from the group consisting of diethyl tartrate, diisopropyl tartrate, and dibenzyl tartrate.

6. The process according to any one of claims 1 to 5, wherein the oxidizing agent is an aqueous solution of t-butyl hydroperoxide or cumene hydroperoxide.

7. The process according to claim 6, wherein the oxidizing agent is cumene hydroperoxide.

8. The method according to any one of claims 1 to 7, wherein the solvent is selected from the group consisting of toluene, chloroform, and ethyl acetate.

9. The process according to claim 8, wherein the solvent is toluene.

10. The method according to any one of claims 1 to 9, wherein the optically active compound is an (R)-form optically active compound, and the chiral diol compound is an (S,S)-tartaric acid diester represented by formula (Va).

11. The method according to any one of claims 1 to 9, wherein the optically active compound is an (S)-form optically active compound, and the chiral diol compound is an (R,R)-tartaric acid diester represented by formula (Vb).

12. The following formula (III) 【Chemistry 3】 [In the formula, R represents a hydrogen atom or a hydroxyl group.] reacting a salt selected from the group consisting of a fumarate, a mandelate, and a sulfonate of a compound represented by the formula: with a titanium compound, a chiral diol compound, a reactant including water, and an oxidizing agent in a solvent; The product of the above process is represented by the following formula (IV): 【Chemistry 4】 [In the formula, * indicates that the compound is optically active, and R indicates a hydrogen atom or a hydroxyl group.] isolating a salt selected from the group consisting of a fumarate, a mandelate and a sulfonate of an optically active compound represented by the formula: exchanging the salt. The following formula (VIII) 【Chemistry 9】 [In the formula, * indicates that the compound is optically active, and R indicates a hydrogen atom or a hydroxyl group.] A method for producing a hydrochloride salt of an optically active compound represented by the following formula: The titanium compound is titanium tetraisopropoxide, The chiral diol compound is selected from a tartaric acid diester represented by the following formula (Va) and a tartaric acid diester represented by the following formula (Vb): Manufacturing method: 【Chemistry 5】 [In the formula, R 1 represents an optionally substituted C 2-6 alkyl group or benzyl.] 【Chemistry 6】 [The symbols in the formula are as defined above.]

13. The method according to claim 12, wherein the salt selected from the group consisting of fumarate, mandelate and sulfonate is a mandelate.

14. The method according to claim 12 or 13, wherein R is a hydrogen atom.

15. The optically active compound is an optically active compound of the (R) form, and the chiral diol compound is represented by the following formula (Va): 【Chemistry 5】 [In the formula, R 1 is an optionally substituted C 2-6 It represents an alkyl group or benzyl. The method according to any one of claims 12 to 14, wherein the (S,S)-tartaric acid diester is represented by the following formula:

16. The optically active compound is an (S) optically active compound, and the chiral diol compound is represented by the following formula (Vb): 【Chemistry 6】 [In the formula, R 1 is an optionally substituted C 2-6 It represents an alkyl group or benzyl. The method according to any one of claims 12 to 14, wherein the (R,R)-tartaric acid diester is represented by the following formula:

Citation Information

Patent Citations

  • A Novel Antiarrhythmic and Heart Failure Agent Targeting Leakage of the Ryanodine Receptor (ryr2)

    JP2008534497A

  • Agents for the prevention and treatment of disorders involving the regulation of ryr receptors

    JP2009506034A

  • 1,4-benzothiazepine derivative, preparation method thereof and application thereof

    JP2010195759A

  • 1,4-benzothiazepine-s-oxide derivative, pharmaceutical composition employing the same, and use therefor

    JP2012046430A

  • Antitumor effect enhancing agent for cancer cell having carcinostatic tolerance

    JP2012131710A